| Identification | Back Directory | [Name]
BAY-218 | [CAS]
2162982-11-6 | [Synonyms]
BAY-218
CPD3504
BAY-2335218
AHR antagonist 1
BAY2335218;BAY-2335218;BAY 2335218;BAY218;BAY 218;BAY-218
(S)-6-(4-Chlorophenyl)-2-(3-fluorophenyl)-N-(1-hydroxypropan-2-yl)-3-oxo-2，3-dihydropyridazine-4-carboxamide
6-(4-chlorophenyl)-2-(3-fluorophenyl)-N-[(2S)-1-hydroxypropan-2-yl]-3-oxo-2,3-dihydropyridazine-4-carboxamide
4-Pyridazinecarboxamide, 6-(4-chlorophenyl)-2-(3-fluorophenyl)-2,3-dihydro-N-[(1S)-2-hydroxy-1-methylethyl]-3-oxo- | [Molecular Formula]
C20H17ClFN3O3 | [MOL File]
2162982-11-6.mol | [Molecular Weight]
401.82 |
| Chemical Properties | Back Directory | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:80.0(Max Conc. mg/mL);199.09(Max Conc. mM)
Ethanol:20.0(Max Conc. mg/mL);49.77(Max Conc. mM) | [form ]
Solid | [pka]
11.81±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an IC50 of 39.9 nM in in U87 glioblastoma cells. BAY-218 can be used for the research of cancer or conditions with dysregulated immune responses[1]. | [in vivo]
BAY-218 (example 23) (p.o; 30 mg/kg; bid) has good anti-tumor effect combinated with aPD-L1[1]. | Animal Model: | Balb/c mice (subcutaneously CT26 cells)[1] | | Dosage: | 30 mg/kg | | Administration: | p.o, bid | | Result: | Significantly decreased tumors size combinated with aPD-L1. |
| [References]
[1] Norbert Schmees, et al. 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides. WO2017202816A1. |
|
|